RDW Test

Most people glance at their hemoglobin, see a normal number, and move on. But tucked inside every standard complete blood count is a value that tells you something hemoglobin alone cannot: how uniform your red blood cells actually are. When your body is under stress, whether from low-grade inflammation, an iron shortfall you haven't felt yet, or the early stirrings of cardiovascular disease, it starts producing red blood cells of uneven sizes. RDW (red cell distribution width) captures that unevenness in a single number.

What makes RDW remarkable is the gap between how routine it is and how much it reveals. A study of over 3 million adults found that people with the highest RDW values were more than twice as likely to die over a median of nearly seven years compared to those in the middle range. That predictive power held up for heart attacks, strokes, cancer, and hospitalizations, even after accounting for age, sex, and other health conditions. And the signal was there years before anyone felt sick.

What RDW Actually Measures

RDW is not a molecule, a protein, or a hormone. It is a statistical calculation: the degree of variation in the volume of your circulating red blood cells, a property called anisocytosis. Your blood-cell-producing bone marrow normally churns out red blood cells of roughly equal size. When something disrupts that process, whether it is a lack of iron, vitamin B12, or folate, chronic inflammation, oxidative damage (harm caused by unstable molecules called free radicals), or abnormal red blood cell survival, the newly minted cells come out in a wider range of sizes. The automated analyzer that processes your blood sample measures thousands of individual cell volumes and reports how spread out they are as a percentage.

RDW is reported in two formats. RDW-CV (coefficient of variation) expresses the spread as a percentage of the average cell volume, with a standard reference range of 11.5% to 14.5%. RDW-SD (standard deviation) reports the spread in femtoliters (a unit of extremely small volume), typically ranging from 39 to 46 fL. Most labs report RDW-CV by default, and most of the research linking RDW to health outcomes uses this format.

Why It Matters Beyond Anemia

RDW was originally developed to help distinguish between types of anemia. A high RDW with small red blood cells points toward iron deficiency, while a normal RDW with small cells suggests a genetic condition like thalassemia trait. That remains a useful application. But the clinical significance of RDW extends far beyond the blood itself.

Elevated RDW appears in people with cardiovascular disease, diabetes, chronic kidney disease, liver disease, chronic lung disease, and several cancers, even when they are not anemic. The likely explanation is that RDW functions as an integrative stress marker. It does not point to one specific disease. Instead, it reflects the cumulative burden of inflammation, oxidative damage, and nutritional strain on your body's ability to produce healthy, uniform red blood cells. Inflammatory signaling molecules (cytokines) interfere with the hormonal signals that drive red blood cell maturation, producing cells of inconsistent size. This makes RDW a kind of biological barometer: it rises when your body's internal systems are under strain, often well before a specific disease announces itself.

Mortality Risk

The most striking finding about RDW is its relationship with death from any cause. In middle-aged and older adults from a large national survey, those in the highest RDW group were roughly twice as likely to die over the follow-up period as those in the lowest group, even after adjusting for iron status, folate, B12, inflammation, and existing diseases. Every 1% increase in RDW in older adults has been linked to a 14% increase in mortality risk in a meta-analysis.

The dose-response pattern is consistent across populations. In the Alberta study of over 3.1 million adults followed for nearly seven years, mortality risk climbed steadily from the middle of the RDW distribution upward.

What this means for you: even within the "normal" reference range, your position matters. Risk does not jump suddenly at a cutoff. It rises gradually, which is why tracking your personal trend is more useful than comparing a single result to a universal threshold.

Heart Disease and Stroke

RDW predicts cardiovascular events across multiple populations. In a study of 240,477 healthy UK Biobank volunteers with no baseline cardiovascular disease, those with RDW at or above 15% were about 1.7 times as likely to develop coronary artery disease and significantly more likely to develop heart failure or have a stroke over the following four to nine years. A meta-analysis combining 28 studies and over 100,000 participants found that each 1% increase in RDW was associated with a 12% increase in the risk of death from any cause among people with cardiovascular disease and a 12% increase in major adverse cardiac events.

In people who already have heart failure, RDW carries added weight. Each 1% increase has been linked to roughly a 10% increase in mortality risk. Combining RDW with NT-proBNP (a protein released when the heart is under strain) improves risk prediction beyond either marker alone. The mechanisms behind this likely include a mix of inflammation, iron dysregulation, kidney strain, and nutritional deficiency that together compromise red blood cell production.

Cancer Risk

Elevated RDW is linked to both the development and the prognosis of cancer. In the UK Biobank study, healthy volunteers with high RDW were about 1.4 times as likely to be diagnosed with cancer overall, nearly twice as likely to develop colorectal cancer, and nearly three times as likely to develop leukemia. A large prospective study of nearly 456,000 participants confirmed this pattern: RDW showed a linear positive relationship with overall cancer risk over roughly 11 years, with stronger associations for blood cancers and kidney cancer.

For people already diagnosed with cancer, a meta-analysis of 49 studies found that an elevated RDW before treatment predicted worse overall survival. A separate meta-analysis of 16 studies showed that high RDW was associated with about a 47% higher risk of dying from the cancer and a 91% higher risk of disease recurrence.

Other Disease Associations

In a Swedish cohort of over 27,000 adults followed for about 20 years, those in the highest RDW quartile had a 39% higher risk of dying from cardiovascular disease, a 27% higher risk of dying from cancer, and a 47% higher risk of dying from respiratory disease compared to the lowest quartile. These associations held after adjusting for standard confounders. RDW has also been linked to outcomes in chronic kidney disease, liver disease, diabetes, venous blood clots, and community-acquired pneumonia.

Reference Ranges

RDW increases with age, rising by roughly 6% from the youngest to oldest adult age groups. Women tend to have slightly higher values and greater variation over time than men. Black individuals have modestly higher average RDW than White individuals. These differences are biological, not artifacts of the lab process, and they do not change the relationship between RDW and health outcomes.

These tiers are drawn from published population research. Your lab may use slightly different cutpoints depending on the analyzer and reference population. Compare your results within the same lab over time for the most meaningful trend. Because RDW rises with age, an upward drift over decades is expected, but a sudden jump or an accelerating upward trend deserves investigation.

Tracking Your Trend

A single RDW value is a snapshot. Its real power emerges when you track it over time. Red blood cells live about 120 days, so meaningful shifts in RDW take weeks to months to appear. That lag makes serial testing more informative than any one reading: a stable RDW over years is reassuring, while a rising trend may signal developing inflammation, nutritional decline, or chronic disease before symptoms appear.

The within-person variation for RDW is low, ranging from about 0.3% to 2.5%. This means that a change of more than a few percentage points from your personal baseline is likely real, not noise. Population-wide reference ranges are less useful for RDW than for many other biomarkers because your own baseline is more informative than where you fall in a crowd. Get a baseline when you are feeling well, retest in three to six months if you are making lifestyle or dietary changes, and monitor at least annually thereafter. If your value is rising, investigate possible causes: iron or B12 depletion, worsening inflammation, or a chronic condition that may not yet be obvious.

The UK Biobank study found that a single elevated RDW reading predicted disease onset four and a half to nine years later. That kind of lead time is exactly what prevention-minded testing is for.

When Results Can Be Misleading

Acute illness is the most common reason for a misleading RDW result. Conditions that reduce oxygen delivery, including pneumonia, heart failure flares, pulmonary embolism, sepsis, and significant blood loss, trigger your body to pump out larger-than-normal red blood cells to compensate. This drives RDW up within days, and the elevation can persist for up to six months after the event resolves. If you have been hospitalized or seriously ill in the past several months, your RDW may still reflect that episode rather than your baseline health.

Blood transfusions introduce donor red blood cells of different sizes, temporarily raising RDW. Recent surgery can have a similar effect through blood loss and the inflammatory response.

Environmental exposures to cadmium and lead are associated with higher RDW, with the effect more pronounced in women. If you have occupational or environmental heavy metal exposure, this could shift your reading upward.

A single exercise session or a recent meal does not meaningfully alter RDW. You do not need to fast or avoid the gym before testing. Short-term dietary changes also do not affect the reading, because RDW reflects the accumulated production of red blood cells over the past several months, not what you ate yesterday.

Heredity and Baseline Variation

Genetic studies estimate that 29% to 34% of the variation in RDW is inherited. Some of the genes involved overlap with pathways related to aging, telomere maintenance (the protective caps on chromosomes that shorten with age), and age-related macular degeneration. This means your starting point for RDW is partly determined by your genetics, reinforcing why your own trend over time is more meaningful than any universal cutoff.